Symbol | Exchange | Currency |
|---|
Aptose Biosciences APTO+65%,Brainstorm Cell Therapeutics BCLI +13%, Benitec Biopharma (BNTC) -24%, Second Sight Medical Products EYES -22%
Nasdaq makes its way into positive territory as Dow's gain nears 350 points
Shares of Second Sight Medical Products Inc. tumbled 25% to pace all premarket decliners on Wednesday, after the implantable visual prosthetics company announced a large private...
For Immediate ReleaseChicago, IL – April 4, 2019 - Stocks in this week’s article are VALE S.A. (NYSE:VALE) , Second Sight Medical Products Inc. (NASDAQ:EYES) ,...
Bargain hunting or looking for stocks with a low price-to-earnings (P/E) ratio is among the widely-used investing strategies. Investors believe that the lower the P/E, the higher...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Buy | Strong Buy | Buy |
| Technical Indicators | Sell | Strong Sell | Strong Buy | Strong Sell | Buy |
| Summary | Neutral | Sell | Strong Buy | Neutral | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 71.75 | 73.00 | 70.25 | -1.08 | -1.48% | 316.31K | NASDAQ | |||
| 10.67 | 11.75 | 10.62 | -0.5200 | -4.65% | 4.86M | NASDAQ | |||
| 24.04 | 24.35 | 23.37 | +0.63 | +2.69% | 54.08M | NYSE | |||
| 71.19 | 71.45 | 69.91 | -0.03 | -0.04% | 15.66M | NYSE | |||
| 152.33 | 152.40 | 149.85 | +2.23 | +1.49% | 666.27K | NYSE | |||
| 46.01 | 46.22 | 45.50 | +0.49 | +1.08% | 1.29M | NYSE | |||
| 29.71 | 30.05 | 28.50 | +0.33 | +1.12% | 2.59M | NASDAQ | |||
| 0.666 | 0.00 | 0.00 | -0.038 | -5.45% | 5.32M | NASDAQ | |||
| 57.49 | 57.80 | 57.25 | -0.11 | -0.19% | 13.87M | NYSE | |||
| 7.55 | 7.70 | 7.45 | -0.17 | -2.20% | 4.46M | NYSE | |||
| 129.03 | 130.53 | 128.18 | -1.08 | -0.83% | 2.39M | NASDAQ | |||
| 419.72 | 420.59 | 416.23 | +0.62 | +0.15% | 213.38K | NYSE | |||
| 156.70 | 157.72 | 152.32 | -2.30 | -1.45% | 4.17M | NASDAQ | |||
| 23.31 | 25.35 | 21.38 | +2.61 | +12.61% | 105.28M | NYSE | |||
| 41.80 | 42.75 | 40.03 | -1.77 | -4.06% | 1.44M | NASDAQ |
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.